Re2O and Rejuran are both injections that place material into the skin. When choosing, first settle what goes into today's syringe. What Rejuran places is PN (sodium polynucleotide).
3-line summary
Re2O places hADM from donated human dermis; Rejuran places PN.
Published human trials compared each with hyaluronic acid, and did not place the two materials side by side on one face.
Re2O measurements ended at about five months, and in the Rejuran eye area, improvement rates for elasticity and hydration declined over time.
What goes into the syringe
Even with the same kind of injection, the starting raw material differs. Re2O places finely processed human acellular dermal matrix (hADM) from donated human skin, filling in a tissue scaffold in which collagen and elastin remain. Manufacturing is by L&C Bio, and supply in Korea is by Humedix, according to reports. Processing of the raw material continues in the Re2O raw-material guide.
Rejuran is an injection that places PN obtained from fish. Korean researchers record Rejuran as a medical device, and Re2O trial records record Re2O as human tissue. Treatment pages are the Re2O treatment information and the Rejuran treatment information.
| Item | Re2O | Rejuran |
|---|---|---|
| Material placed | hADM from donated dermis | PN |
| Classification recorded in Korea | Human tissue | Medical device |
| Comparator in the trial | Hyaluronic acid (Re2O in a mixed formulation) | Hyaluronic acid (eye area) |
| Recorded session count | Three sessions at one-month intervals | Three sessions at 2-week intervals |
※ The Re2O trial syringe also contained hyaluronic acid, saline, and an anesthetic. One of the authors served as an advisor on the manufacturer's product development. If today's formulation differs from that mix, the recovery course is not mapped onto that observation period as-is.
Start with whether it is the cheeks or the eye area
The published Re2O trial split faces with uneven cheek texture into left and right. One side received an injection mixed with Re2O; the other side received hyaluronic acid only. Measures of density, elasticity, wrinkles, pores, and hydration moved more on the mixed side, and measurement ended at about five months. The details of those numbers are in the Re2O effects information.
A Rejuran eye-area study that recorded the product name placed PN and hyaluronic acid on the left and right of one face. Roughness and pores lasted longer on the PN side, and improvement rates for elasticity and hydration declined over time. The pattern seen around the eyes is in the Rejuran effects information.
| The plan you heard today | What to check against |
|---|---|
| Re2O mixed with hyaluronic acid and placed in the cheeks | Whether it is the same formulation as the published Re2O trial |
| Rejuran only placed in the eye area | Whether it is the same site as the left–right eye-area comparison |
| Both materials placed in the same site on the same day | A schedule not covered in the published trials |
When receiving the two materials in sequence
The published trials each compared only with hyaluronic acid. Those data did not set a schedule for stacking them in the same site on the same day. Sequence and interval are decided after recovery is observed. Flow on the day of treatment can be seen in the Re2O treatment process and the Rejuran Healer guide.
In the Re2O trial, serious adverse events were counted as 0 reported cases, and temporary redness and mild swelling settled without treatment. The Rejuran eye-area study also counted serious adverse events as 0 reported cases, and redness, itching, and irritation were reported in some participants. Needle marks and schedule are covered in the Rejuran pain and recovery guide.
Questions to ask as written in consultation
So that cost estimates and trial records are not mixed, write down the following as a single line before booking. Consent items for human-derived materials are in the consultation on human tissue-derived materials.
- □ Whether today's name is Re2O or Rejuran
- □ If it is Re2O, how much hyaluronic acid is mixed into the syringe
- □ Whether to look at the cheeks or the eye area
- □ Whether to look at a one-month interval or 2 weeks
- □ Whether breastfeeding, autoimmunity, anticoagulants, a recent facial procedure, and active infection have already been disclosed
Frequently asked questions
Q1. Does it hurt?
Both are injections placed into the dermis with a needle. The Re2O trial formulation contained an anesthetic, and redness and mild swelling immediately afterward were reported. In the Rejuran eye-area study, redness, itching, and irritation were reported in some participants.
Q2. How many sessions?
Re2O trial registration information listed three sessions at one-month intervals. The Rejuran eye-area study was three sessions at 2-week intervals. Values after a single session are outside the measurement plan of the published Re2O trial.
Q3. How long does it last?
If the duration you were told goes beyond five months, confirm the formulation and site that grounded that figure. The last time point at which Re2O measured the skin is about five months, and in the Rejuran eye-area study, improvement rates for elasticity and hydration declined over time.
Q4. Can they be received together?
Because the materials differ, they are not stacked in the same site on the same day. During the Re2O trial period, the condition was not to receive other facial procedures at the same time. If you currently have a facial procedure underway, the next appointment is set after recovery is observed.
Q5. Who should postpone the schedule?
Conditions that kept people out of the Re2O trial are breastfeeding, autoimmunity, severe allergy, a recent facial procedure, and recent anticoagulants. The Rejuran eye-area study is also an injectable, and skin with infection or inflammation is disclosed before the appointment. Shared criteria are in the treatment safety information.
Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.
This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.
Sources
- Injectable particulate hADM skin-booster comparative trial in humans (PMID 41828422, PMC12985180) — Abstract and full text confirmed. Elravie Re2O mixed with hyaluronic acid, saline, and an anesthetic was placed in one cheek; hyaluronic acid only on the other side. Measured for about five months. Density, elasticity, wrinkles, pores, hydration, and other measures moved more on the mixed side. Serious adverse events 0; temporary erythema and swelling. One author (Ju Hee Lee) advised on Elravie Re2O development. Limitations: small scale, mixed formulation, short term. No retraction or expression of concern on Europe PMC.
- Registration information for the same trial (NCT07155278) — Registration text confirmed. 3 intradermal injections at one-month intervals. Records Re2O as human tissue, MFDS tissue-bank authorization. Exclusion: breastfeeding, autoimmunity, severe allergy, facial procedures within the past 12 months, anticoagulants within 2 weeks of screening. Limitations: this is a plan and eligibility criteria, not a results table.
- Left–right comparison of PN vs hyaluronic acid around the eyes (PMID 32248707) — Abstract confirmed. 3 sessions at 2-week intervals. Roughness and pores on the PN side; improvement rates for elasticity and hydration declined over time. No serious adverse events reported. The product name is not in the abstract; the review table below records it as Rejuran PN. No retraction or expression of concern on Europe PMC.
- Systematic review of PN injections in the aesthetic field (PMID 39645667, PMC11845969) — Confirmed through the table in the full text. The Lee 2022 row records Rejuran PN, eye area and under the eyes, observation 28 weeks, all women, and local reactions (erythema, itching, irritation). Among the authors: an education officer of a PN product distributor, and a manufacturer advisor. Limitations: the included Pak 2014 (PMID 25473210) was retracted in 2016. The body does not use numbers from that retracted paper.
- Narrative review organizing PN and PDRN classification in Korea (PMID 40871045, PMC12388916) — Full-text table confirmed. Records Rejuran as a medical device as an example of PN in Korea. Authors declared no conflicts of interest; university research funding. Limitations: a narrative review, not the original authorization document. Authorization numbers are not used in the body.
- The Bio: L&C Bio–Humedix supply agreement (2024.11.18) — Article text confirmed. Original developer L&C Bio, supplier in Korea Humedix. Statements on pores and pigmentation are company description, so they are not used in the body.
Related reading
Sources
Discuss options for your current needs
We review your current health and prior procedures before explaining appropriate options and their limits.
